

14. The solution according to claim 12, wherein the solution comprises a component for adjusting the PH to a physiological value ranging from 4.8 to 8.1.

15. The solution according to claim 10, wherein the solution comprises a complementary substance to prevent the transformation of the PpIX into a heme by iron complexing in the live cells.

AA 16. The solution according to claim 15, wherein said complementary substance is an EDTA (diaminoethyl tetra acetate).

17. The solution according to claim 15, wherein said complementary substance is deferroxamine.

18. The solution according to claim 15, wherein said complementary substance is desferal.

#### REMARKS

Please enter the above before consideration of this application. With respect to the above newly entered claims, please note that the subject matter of the originally filed claims is editorially revised and rewritten to bring that subject matter into conformity with the United States claim format.

In the event that there are any fee deficiencies or additional fees are payable, please charge the same or credit any overpayment to our Deposit Account (Account No. 04-0213).

Respectfully submitted,

*Michael J. Bujold*

Michael J. Bujold, Reg. No. 32,018

**Customer No. 020210**

Davis and Bujold

Fourth Floor

500 North Commercial Street

Manchester NH 03101

Telephone 603-624-9220

Facsimile 603-624-9229

E-mail: [patent@davisandbujold.com](mailto:patent@davisandbujold.com)